protoporphyrin ix has been researched along with Urinary Bladder Neoplasms in 53 studies
protoporphyrin IX: RN given refers to parent cpd; structure in Merck Index, 9th ed, #7685
protoporphyrin : A cyclic tetrapyrrole that consists of porphyrin bearing four methyl substituents at positions 3, 8, 13 and 17, two vinyl substituents at positions 7 and 12 and two 2-carboxyethyl substituents at positions 2 and 18. The parent of the class of protoporphyrins.
Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The mechanism underlying the increased levels of protoporphyrin IX in bladder cancer remains unclear." | 7.83 | Expression of ferrochelatase has a strong correlation in protoporphyrin IX accumulation with photodynamic detection of bladder cancer. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Kuwada, M; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2016) |
| "We evaluated the feasibility of photodynamic diagnosis of bladder cancer by spectrophotometric analysis of voided urine samples after extracorporeal treatment with 5-aminolevulinic acid (ALA)." | 7.81 | Protoporphyrin IX induced by 5-aminolevulinic acid in bladder cancer cells in voided urine can be extracorporeally quantified using a spectrophotometer. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Masaomi, K; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2015) |
| "5-aminolevulinic acid mediated changes in tissue specific fluorescence were studied in bladder cancer." | 7.72 | Fluorescence confocal microscopy and image analysis of bladder cancer using 5-aminolevulinic acid. ( Christopher, C; Hoon, TP; Lau, W; Manivasager, V; Olivo, M, 2003) |
| "5-Aminolevulinic acid (ALA) is a precursor of protoporphyrin IX (PpIX) that is being evaluated for use in photodiagnosis and phototherapy of malignant and nonmalignant disorders." | 6.70 | Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. ( Dalton, JT; Golub, AL; Marcus, SL; Meyer, MC; Straughn, A; Yates, CR; Yin, D, 2002) |
| " The usefulness of intracellularly accumulated endogenous protoporphyrin IX (PPIX), induced by 5-aminolevulinic acid (ALA), for diagnosis of early bladder cancer and the correlation with cystoscopic, microscopic, and fluorescence findings was investigated." | 5.07 | Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid. ( Baumgartner, R; Ehsan, A; Hofstädter, F; Hofstetter, A; Knuechel, R; Kriegmair, M; Lumper, W; Steinbach, P, 1994) |
| "Hexaminolevulinate (HAL) induced Protoporphyrin IX (PpIX) fluorescence is commonly used to differentiate cancer cells from normal cells in vivo, as for instance in blue light cystoscopy for bladder cancer diagnosis." | 4.02 | Improving hexaminolevulinate enabled cancer cell detection in liquid biopsy immunosensors. ( Chan, KM; Gleadle, J; Li, J; MacGregor, M; Michl, TD; Vasilev, K, 2021) |
| "The mechanism underlying the increased levels of protoporphyrin IX in bladder cancer remains unclear." | 3.83 | Expression of ferrochelatase has a strong correlation in protoporphyrin IX accumulation with photodynamic detection of bladder cancer. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Kuwada, M; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2016) |
| "We evaluated the feasibility of photodynamic diagnosis of bladder cancer by spectrophotometric analysis of voided urine samples after extracorporeal treatment with 5-aminolevulinic acid (ALA)." | 3.81 | Protoporphyrin IX induced by 5-aminolevulinic acid in bladder cancer cells in voided urine can be extracorporeally quantified using a spectrophotometer. ( Anai, S; Chihara, Y; Fujimoto, K; Hirao, Y; Masaomi, K; Miyake, M; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2015) |
| "This study shows that PVP-hypericin appears to have great potential as a photodynamic agent against non-muscle-invasive bladder cancers after intravesical administration, with a limited risk of affecting the deeper layers of the bladder." | 3.77 | Biodistribution of PVP-hypericin and hexaminolevulinate-induced PpIX in normal and orthotopic tumor-bearing rat urinary bladder. ( de Witte, PA; Hettinger, K; Van Cleynenbreugel, B; Van Poppel, H; Vandepitte, J, 2011) |
| "5-aminolevulinic acid mediated changes in tissue specific fluorescence were studied in bladder cancer." | 3.72 | Fluorescence confocal microscopy and image analysis of bladder cancer using 5-aminolevulinic acid. ( Christopher, C; Hoon, TP; Lau, W; Manivasager, V; Olivo, M, 2003) |
| "A major problem diagnosing bladder cancer using conventional white-light cystoscopy is that flat and tiny papillary neoplasms can be overlooked." | 2.70 | Diagnostic efficacy of fluorescence cystoscopy for detection of urothelial neoplasms. ( Chai, SE; Choi, HY; Hong, JH; Jeon, SS; Kang, I, 2001) |
| "5-Aminolevulinic acid (ALA) is a precursor of protoporphyrin IX (PpIX) that is being evaluated for use in photodiagnosis and phototherapy of malignant and nonmalignant disorders." | 2.70 | Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. ( Dalton, JT; Golub, AL; Marcus, SL; Meyer, MC; Straughn, A; Yates, CR; Yin, D, 2002) |
| "A better understanding of why cancer cells fluoresce with 5-ALA would improve its use in cancer diagnostics and therapies." | 2.61 | In order for the light to shine so brightly, the darkness must be present-why do cancers fluoresce with 5-aminolaevulinic acid? ( Gleadle, JM; MacGregor, MN; McNicholas, K, 2019) |
| "Bladder cancer is the most common tumor of the urinary tract, with a worldwide incidence of 8." | 2.49 | Innovations in the endoscopic management of bladder cancer: is the era of white light cystoscopy over. ( Ambrosini, E; Frea, B; Giona, S; Gontero, P; Gurioli, A; Oderda, M; Peraldo, F; Soria, F, 2013) |
| "Recurrent bladder cancer is due to tumor cell implantation, incomplete resection, and multicentric neoplastic changes throughout the bladder." | 2.41 | Endoscopic fluorescence diagnosis and laser treatment of transitional cell carcinoma of the bladder. ( Frimberger, D; Hofstetter, A; Zaak, D, 2000) |
| "The accumulation of PpIX in bladder cancer cells was significantly higher than in non-cancer cells, both cultured monolayer cells and cells in suspension." | 1.51 | Biosensor device for the photo-specific detection of immuno-captured bladder cancer cells using hexaminolevulinate: An ex-vivo study. ( Chan, KM; Gleadle, J; Li, J; MacGregor, M; McNicholas, K; Shirazi, HS; Vasilev, K, 2019) |
| "Non-muscle invasive bladder cancer can be missed during white light endoscopy in up to 50% of cases." | 1.42 | Laser-induced autofluorescence spectroscopy: can it be of importance in detection of bladder lesions? ( Aboumarzouk, O; Ahmad, S; Buist, R; Eljamel, S; Kata, SG; Moseley, H; Nabi, G; Valentine, R, 2015) |
| "5-Aminolevulinic acid (ALA) is a widely used photodynamic therapy (PDT) prodrug in the clinic." | 1.42 | Immobilization of ALA-Zn(II) Coordination Polymer Pro-photosensitizers on Magnetite Colloidal Supraparticles for Target Photodynamic Therapy of Bladder Cancer. ( Guo, J; Sun, C; Tan, J; Wang, C; Xu, K, 2015) |
| " Lipophilicity is one of the key parameters defining the bioavailability of a topically applied drug." | 1.31 | 5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. ( Juillerat-Jeanneret, L; Lange, N; Uehlinger, P; van den Bergh, H; Wagnières, G; Zellweger, M, 2000) |
| " The elimination half-life of 5-ALA amounted to 0." | 1.31 | Intravesical administration of 5-aminolevulinic acid (5-ALA). Safety and pharmacokinetics of 5-ALA and its metabolite protoporphyrin IX. ( Birkel, M; Popken, G; Schultze-Seemann, W; Seiler, KU; Wetterauer, U, 2000) |
| "The prognosis of superficial bladder cancer in terms of recurrence and disease progression is related to bladder tumor multiplicity and the presence of concomitant "plane" tumors such as high-grade dysplasia and carcinoma in situ." | 1.30 | Clinical assessment of fluorescence cytoscopy during transurethral bladder resection in superficial bladder cancer. ( Forrer, M; Graber, P; Guillou, L; Jichlinski, P; Leisinger, HJ; Mizeret, J; Oswald, M; Schmidlin, F; Van den Bergh, H; Wagnières, G, 1997) |
| "The prognosis of superficial bladder cancer in terms of local recurrence and transformation into invasive cancer is related to the multiplicity of tumor sites and the concomitant presence of "flat" tumours, such as dysplasia and carcinoma in situ." | 1.30 | [The clinical value of fluorescence cystoscopy in the detection of superficial transitional epithelial cell carcinoma of the bladder]. ( Forrer, M; Graber, P; Guillou, L; Jichlinski, P; Leisinger, HJ; Mizeret, J; Schmidlin, F; Van den Bergh, H; Wagniéres, G, 1997) |
| "Rats bearing orthotopic bladder tumors were treated either intravesically or intravenously with graded doses of 5-aminolevulinic acid (ALA) or PII." | 1.30 | Biodistribution of Photofrin II and 5-aminolevulinic acid-induced protoporphyrin IX in normal rat bladder and bladder tumor models: implications for photodynamic therapy. ( Brown, KM; Lown, JW; McCallum, TJ; Miller, GG; Moore, RB; Tulip, J; Xiao, Z, 1998) |
| "This study used bladder cancer cells, incubated with ALA at various oxygen tensions and H+ ion concentrations, and assessed the effects on PpIX generation and PDT sensitivity." | 1.30 | The influence of hypoxia and pH on aminolaevulinic acid-induced photodynamic therapy in bladder cancer cells in vitro. ( Brown, NJ; Reed, MW; Wyld, L, 1998) |
| "5-Aminolevulinic acid (ALA) is a precursor of heme biosynthesis." | 1.29 | Biodistribution and phototoxicity of 5-aminolevulinic acid-induced PpIX in an orthotopic rat bladder tumor model. ( Bachor, R; Flotte, T; Hasan, T; Iinuma, S, 1995) |
| "Following transurethral resection of bladder cancer, the fate of patients is clearly related to the presence or absence of precancerous or malignant lesions in the remaining mucosa." | 1.29 | [Photodynamic diagnosis of urothelial neoplasms after intravesicular instillation of 5-aminolevulinic acid]. ( Baumgartner, R; Ehsan, A; Hofstädter, F; Hofstetter, A; Knüchel, R; Kriegmair, M; Lumper, W; Steinbach, P, 1994) |
| "5-Aminolevulinic acid was instilled prior to cystoscopy and biopsies were taken of lesions that were either fluorescing or nonfluorescing." | 1.29 | Intravesical instillation of 5-aminolevulinic acid: the fluorescent metabolite is limited to urothelial cells. ( Baumgartner, R; Hofstädter, F; Knüchel, R; Kriegmair, M; Steinbach, P, 1994) |
| "Aminolevulinic acid (ALA) is a precursor of protoporphyrin IX (PP IX), a potent photosensitizer." | 1.29 | Aminolevulinic acid for photodynamic therapy of bladder carcinoma cells. ( Bachor, R; Hautmann, R; Reich, E; Rück, A, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 21 (39.62) | 18.2507 |
| 2000's | 20 (37.74) | 29.6817 |
| 2010's | 11 (20.75) | 24.3611 |
| 2020's | 1 (1.89) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, KM | 2 |
| Vasilev, K | 2 |
| Shirazi, HS | 1 |
| McNicholas, K | 2 |
| Li, J | 2 |
| Gleadle, J | 2 |
| MacGregor, M | 2 |
| MacGregor, MN | 1 |
| Gleadle, JM | 1 |
| Michl, TD | 1 |
| Inoue, K | 4 |
| Fukuhara, H | 2 |
| Kurabayashi, A | 3 |
| Furihata, M | 3 |
| Tsuda, M | 1 |
| Nagakawa, K | 1 |
| Fujita, H | 2 |
| Utsumi, K | 2 |
| Shuin, T | 3 |
| Soria, F | 1 |
| Gurioli, A | 1 |
| Peraldo, F | 1 |
| Oderda, M | 1 |
| Giona, S | 1 |
| Ambrosini, E | 1 |
| Frea, B | 1 |
| Gontero, P | 1 |
| Hagiya, Y | 1 |
| Matsumoto, K | 1 |
| Endo, Y | 1 |
| Nakajima, M | 1 |
| Tanaka, T | 1 |
| Okura, I | 1 |
| Ogura, S | 1 |
| Aboumarzouk, O | 1 |
| Valentine, R | 1 |
| Buist, R | 1 |
| Ahmad, S | 1 |
| Nabi, G | 1 |
| Eljamel, S | 1 |
| Moseley, H | 1 |
| Kata, SG | 1 |
| Nakai, Y | 2 |
| Anai, S | 2 |
| Onishi, S | 2 |
| Masaomi, K | 1 |
| Tatsumi, Y | 2 |
| Miyake, M | 2 |
| Chihara, Y | 2 |
| Tanaka, N | 2 |
| Hirao, Y | 2 |
| Fujimoto, K | 2 |
| Kuwada, M | 1 |
| Tan, J | 1 |
| Sun, C | 1 |
| Xu, K | 1 |
| Wang, C | 1 |
| Guo, J | 1 |
| Berrahmoune, S | 1 |
| Fotinos, N | 1 |
| Bezdetnaya, L | 2 |
| Lange, N | 5 |
| Guedenet, JC | 1 |
| Guillemin, F | 2 |
| D'Hallewin, MA | 1 |
| Karashima, T | 1 |
| Kamada, M | 1 |
| Sasaki, J | 1 |
| Vandepitte, J | 1 |
| Van Cleynenbreugel, B | 1 |
| Hettinger, K | 1 |
| Van Poppel, H | 1 |
| de Witte, PA | 1 |
| Manivasager, V | 2 |
| Heng, PW | 1 |
| Hao, J | 1 |
| Zheng, W | 1 |
| Soo, KC | 1 |
| Olivo, M | 2 |
| Lau, W | 1 |
| Hoon, TP | 1 |
| Christopher, C | 1 |
| Marti, A | 2 |
| Jichlinski, P | 7 |
| Ballini, JP | 1 |
| Guillou, L | 5 |
| Leisinger, HJ | 5 |
| Kucera, P | 3 |
| Hjelde, A | 1 |
| Gederaas, OA | 1 |
| Krokan, HE | 1 |
| Brubakk, AO | 1 |
| Tauber, S | 1 |
| Stepp, H | 3 |
| Meier, R | 1 |
| Bone, A | 1 |
| Hofstetter, A | 7 |
| Stief, C | 1 |
| Vaucher, L | 1 |
| Ritter-Schenk, C | 1 |
| van den Bergh, H | 7 |
| Cunderlíková, B | 1 |
| Wahlqvist, R | 1 |
| Berner, A | 1 |
| Vasovic, V | 1 |
| Warloe, T | 1 |
| Nesland, JM | 1 |
| Peng, Q | 1 |
| Forster, TH | 1 |
| Wyler, S | 1 |
| Ruszat, R | 1 |
| Gasser, TC | 1 |
| Bachmann, A | 1 |
| Mizeret, J | 4 |
| Forrer, M | 5 |
| Wagnière, G | 1 |
| Schmidlin, F | 4 |
| Graber, P | 4 |
| Iinuma, S | 2 |
| Bachor, R | 2 |
| Flotte, T | 1 |
| Hasan, T | 2 |
| Kriegmair, M | 6 |
| Baumgartner, R | 9 |
| Knüchel, R | 5 |
| Ehsan, A | 3 |
| Steinbach, P | 5 |
| Lumper, W | 3 |
| Hofstädter, F | 4 |
| Knuechel, R | 4 |
| Farshi, SS | 1 |
| Ortel, B | 1 |
| König, K | 1 |
| Schneckenburger, H | 1 |
| Rück, A | 2 |
| Steiner, R | 1 |
| Weingandt, H | 1 |
| Stepp, HG | 1 |
| Rick, K | 1 |
| Reich, E | 1 |
| Hautmann, R | 1 |
| Wagnières, G | 5 |
| Oswald, M | 1 |
| Glanzmann, T | 1 |
| Braichotte, D | 1 |
| Zimmer, G | 1 |
| Heil, P | 1 |
| Stocker, S | 1 |
| Sroka, R | 1 |
| Koenig, F | 1 |
| McGovern, FJ | 1 |
| Xiao, Z | 1 |
| Miller, GG | 1 |
| McCallum, TJ | 1 |
| Brown, KM | 1 |
| Lown, JW | 1 |
| Tulip, J | 1 |
| Moore, RB | 2 |
| Wyld, L | 2 |
| Reed, MW | 2 |
| Brown, NJ | 2 |
| Smith, O | 1 |
| Lawry, J | 1 |
| Li, G | 1 |
| Szewczuk, MR | 1 |
| Raptis, L | 1 |
| Johnson, JG | 1 |
| Weagle, GE | 1 |
| Pottier, RH | 1 |
| Kennedy, JC | 1 |
| Zellweger, M | 2 |
| Zaak, D | 3 |
| Uehlinger, P | 1 |
| Juillerat-Jeanneret, L | 1 |
| Krieg, RC | 2 |
| Fickweiler, S | 1 |
| Wolfbeis, OS | 1 |
| Popken, G | 1 |
| Schultze-Seemann, W | 1 |
| Seiler, KU | 1 |
| Birkel, M | 1 |
| Wetterauer, U | 1 |
| Frimberger, D | 2 |
| Cosserat-Gerardin, I | 1 |
| Notter, D | 1 |
| Vigneron, C | 1 |
| Seidl, J | 1 |
| Rauch, J | 1 |
| Appel, S | 1 |
| Schneede, P | 1 |
| Schmeller, N | 1 |
| Jeon, SS | 1 |
| Kang, I | 1 |
| Hong, JH | 1 |
| Choi, HY | 1 |
| Chai, SE | 1 |
| Gronlund-Pakkanen, S | 1 |
| Wahlfors, J | 1 |
| Makinen, K | 1 |
| Pakkanen, TM | 1 |
| Talja, M | 1 |
| Ala-Opas, M | 1 |
| Alhava, E | 1 |
| Dalton, JT | 1 |
| Yates, CR | 1 |
| Yin, D | 1 |
| Straughn, A | 1 |
| Marcus, SL | 1 |
| Golub, AL | 1 |
| Meyer, MC | 1 |
5 reviews available for protoporphyrin ix and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
In order for the light to shine so brightly, the darkness must be present-why do cancers fluoresce with 5-aminolaevulinic acid?
Topics: Amino Acid Transport Systems; Aminolevulinic Acid; Brain Neoplasms; Coproporphyrinogens; Ferrochelat | 2019 |
Innovations in the endoscopic management of bladder cancer: is the era of white light cystoscopy over.
Topics: Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Transitional Cell; Cystoscopy; False Negative Rea | 2013 |
5-Aminolevulinic acid-mediated photodynamic therapy for bladder cancer.
Topics: Aminolevulinic Acid; Humans; Photochemotherapy; Photosensitizing Agents; Protoporphyrins; Treatment | 2017 |
["... The better to see you with"--phothodynamic diagnostic in superficial bladder cancer].
Topics: Administration, Intravesical; Aminolevulinic Acid; Animals; Carcinoma in Situ; Carcinoma, Papillary; | 2007 |
Endoscopic fluorescence diagnosis and laser treatment of transitional cell carcinoma of the bladder.
Topics: Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystoscopy; Fluorescence; Humans; Laser Therapy; | 2000 |
6 trials available for protoporphyrin ix and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Transitional | 2003 |
Fluorescence photodetection of neoplastic urothelial lesions following intravesical instillation of 5-aminolevulinic acid.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Femal | 1994 |
Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study.
Topics: Aged; Aminolevulinic Acid; Female; Fluorescence; Humans; Male; Middle Aged; Photochemotherapy; Photo | 1999 |
Photodynamic cystoscopy for detection of bladder tumors.
Topics: Adenocarcinoma, Papillary; Administration, Intravesical; Aminolevulinic Acid; Biopsy; Cystoscopy; Di | 1999 |
Diagnostic efficacy of fluorescence cystoscopy for detection of urothelial neoplasms.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Cystoscopy; Female; Fluoresc | 2001 |
Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer.
Topics: Administration, Intravesical; Administration, Oral; Aminolevulinic Acid; Cross-Over Studies; Drug Ad | 2002 |
42 other studies available for protoporphyrin ix and Urinary Bladder Neoplasms
| Article | Year |
|---|---|
Biosensor device for the photo-specific detection of immuno-captured bladder cancer cells using hexaminolevulinate: An ex-vivo study.
Topics: Aminolevulinic Acid; Biosensing Techniques; Cell Line, Tumor; Cystoscopy; Humans; In Vitro Technique | 2019 |
Improving hexaminolevulinate enabled cancer cell detection in liquid biopsy immunosensors.
Topics: Aminolevulinic Acid; Biosensing Techniques; Cell Line, Tumor; Cells, Cultured; Humans; Immunologic T | 2021 |
Photodynamic therapy involves an antiangiogenic mechanism and is enhanced by ferrochelatase inhibitor in urothelial carcinoma.
Topics: Aminolevulinic Acid; Angiogenesis Inhibitors; Animals; Apoptosis; Carcinoma, Transitional Cell; Cell | 2013 |
Expression levels of PEPT1 and ABCG2 play key roles in 5-aminolevulinic acid (ALA)-induced tumor-specific protoporphyrin IX (PpIX) accumulation in bladder cancer.
Topics: Aminolevulinic Acid; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette T | 2013 |
Laser-induced autofluorescence spectroscopy: can it be of importance in detection of bladder lesions?
Topics: Aged; Aged, 80 and over; Humans; Image Interpretation, Computer-Assisted; Lasers; Middle Aged; Optic | 2015 |
Protoporphyrin IX induced by 5-aminolevulinic acid in bladder cancer cells in voided urine can be extracorporeally quantified using a spectrophotometer.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cell Line, Tumor; Female; Humans; Male; Middle | 2015 |
Expression of ferrochelatase has a strong correlation in protoporphyrin IX accumulation with photodynamic detection of bladder cancer.
Topics: Aminolevulinic Acid; Biomarkers, Tumor; Cell Line, Tumor; Cells, Cultured; Cystoscopy; Ferrochelatas | 2016 |
Immobilization of ALA-Zn(II) Coordination Polymer Pro-photosensitizers on Magnetite Colloidal Supraparticles for Target Photodynamic Therapy of Bladder Cancer.
Topics: Aminolevulinic Acid; Blotting, Western; Cell Death; Cell Line, Tumor; Colloids; Ferrosoferric Oxide; | 2015 |
Analysis of differential PDT effect in rat bladder tumor models according to concentrations of intravesical hexyl-aminolevulinate.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Chromatography, High Pressure Liquid; Disease Models | 2008 |
Regulation of 5-aminolevulinic acid-mediated protoporphyrin IX accumulation in human urothelial carcinomas.
Topics: Aminolevulinic Acid; beta-Alanine; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; Carcinoma, Tr | 2009 |
Biodistribution of PVP-hypericin and hexaminolevulinate-induced PpIX in normal and orthotopic tumor-bearing rat urinary bladder.
Topics: Aminolevulinic Acid; Animals; Anthracenes; Antineoplastic Agents; Female; Fluorescence; Perylene; Ph | 2011 |
A study of 5-aminolevulinic acid and its methyl ester used in in vitro and in vivo systems of human bladder cancer.
Topics: Administration, Topical; Aminolevulinic Acid; Animals; Biological Transport, Active; Carcinoma; Cyst | 2003 |
Fluorescence confocal microscopy and image analysis of bladder cancer using 5-aminolevulinic acid.
Topics: Administration, Intravesical; Aminolevulinic Acid; Biomarkers, Tumor; Carcinoma in Situ; Carcinoma, | 2003 |
Lack of effect of hyperoxia on photodynamic therapy and lipid peroxidation in three different cancer cell lines.
Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Colonic Neoplasms; Humans; Hyperoxia; Lipid Peroxida | 2005 |
Integral spectrophotometric analysis of 5-aminolaevulinic acid-induced fluorescence cytology of the urinary bladder.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Transitional Cell; Female; Humans; M | 2006 |
Hexyl-aminolevulinate-mediated photodynamic therapy: how to spare normal urothelium. An in vitro approach.
Topics: Aminolevulinic Acid; Animals; Cell Survival; In Vitro Techniques; Microscopy, Electron, Scanning; Mu | 2007 |
Detection of urinary bladder cancer with flow cytometry and hexaminolevulinate in urine samples.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Biomarkers, Tumor; Carcinoma, Transitional Cell; Cell | 2007 |
[Superficial bladder tumors. Pathological and clinical review and presentation of a new diagnostic method: fluorescence photodetection of transitional epithelial carcinomas based on protoporphyrin IX induction with delta-aminolevulinic acid (5-ALA)].
Topics: Aged; Aged, 80 and over; Algorithms; Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystoscopy; | 1995 |
Biodistribution and phototoxicity of 5-aminolevulinic acid-induced PpIX in an orthotopic rat bladder tumor model.
Topics: Aminolevulinic Acid; Animals; Female; Neoplasm Transplantation; Photochemotherapy; Protoporphyrins; | 1995 |
[Photodynamic diagnosis of urothelial neoplasms after intravesicular instillation of 5-aminolevulinic acid].
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Carcinoma | 1994 |
Intravesical instillation of 5-aminolevulinic acid: the fluorescent metabolite is limited to urothelial cells.
Topics: Administration, Intravesical; Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Papillary; Cell Lin | 1994 |
A mechanistic study of cellular photodestruction with 5-aminolaevulinic acid-induced porphyrin.
Topics: Aminolevulinic Acid; Animals; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cell Division; | 1994 |
In vivo photoproduct formation during PDT with ALA-induced endogenous porphyrins.
Topics: Aminolevulinic Acid; Animals; Female; Humans; Kinetics; Light; Mice; Mice, Nude; Neoplasm Transplant | 1993 |
Cellular fluorescence of the endogenous photosensitizer protoporphyrin IX following exposure to 5-aminolevulinic acid.
Topics: Aminolevulinic Acid; Cell Line; Flow Cytometry; Fluorescence; Humans; Photochemotherapy; Photosensit | 1995 |
Fluorescence cystoscopy following intravesical instillation of 5-aminolevulinic acid: a new procedure with high sensitivity for detection of hardly visible urothelial neoplasias.
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Cystoscopy; Epith | 1995 |
Aminolevulinic acid for photodynamic therapy of bladder carcinoma cells.
Topics: Aminolevulinic Acid; Cell Survival; Humans; Photochemotherapy; Photosensitizing Agents; Protoporphyr | 1996 |
Clinical assessment of fluorescence cytoscopy during transurethral bladder resection in superficial bladder cancer.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Transitional Cell; Cystoscopes; Cyst | 1997 |
Clinical evaluation of a method for detecting superficial surgical transitional cell carcinoma of the bladder by light-induced fluorescence of protoporphyrin IX following the topical application of 5-aminolevulinic acid: preliminary results.
Topics: Administration, Cutaneous; Administration, Intravesical; Adult; Aged; Aged, 80 and over; Aminolevuli | 1997 |
[The clinical value of fluorescence cystoscopy in the detection of superficial transitional epithelial cell carcinoma of the bladder].
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma in Situ; Carci | 1997 |
In vivo fluorescence kinetics of porphyrins following intravesical instillation of 5-aminolaevulinic acid in normal and tumour-bearing rat bladders.
Topics: Administration, Intravesical; Aminolevulinic Acid; Animals; Female; Kinetics; Photosensitizing Agent | 1997 |
Fluorescence detection of bladder carcinoma.
Topics: Aged; Fluorescence; Humans; Light; Male; Photosensitizing Agents; Protoporphyrins; Urinary Bladder N | 1997 |
Biodistribution of Photofrin II and 5-aminolevulinic acid-induced protoporphyrin IX in normal rat bladder and bladder tumor models: implications for photodynamic therapy.
Topics: Aminolevulinic Acid; Animals; Dihematoporphyrin Ether; Disease Models, Animal; Female; Photochemothe | 1998 |
The influence of hypoxia and pH on aminolaevulinic acid-induced photodynamic therapy in bladder cancer cells in vitro.
Topics: Acidosis; Aminolevulinic Acid; Cell Hypoxia; Cell Survival; Humans; Hydrogen-Ion Concentration; Phot | 1998 |
Cell cycle phase influences tumour cell sensitivity to aminolaevulinic acid-induced photodynamic therapy in vitro.
Topics: Aminolevulinic Acid; Cell Cycle; Humans; Photochemotherapy; Photosensitizing Agents; Protoporphyrins | 1998 |
Rodent fibroblast model for studies of response of malignant cells to exogenous 5-aminolevulinic acid.
Topics: 3T3 Cells; Aminolevulinic Acid; Animals; Cell Line, Transformed; Cell Transformation, Neoplastic; Ce | 1999 |
5-Aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells.
Topics: Aminolevulinic Acid; Bronchi; Cell Line; Humans; Hydrogen-Ion Concentration; Kinetics; Lung Neoplasm | 2000 |
Cell-type specific protoporphyrin IX metabolism in human bladder cancer in vitro.
Topics: Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Cell Division; Ferrochelatase; Humans; Hydrox | 2000 |
Intravesical administration of 5-aminolevulinic acid (5-ALA). Safety and pharmacokinetics of 5-ALA and its metabolite protoporphyrin IX.
Topics: Administration, Intravesical; Adult; Aged; Aminolevulinic Acid; Female; Humans; Male; Middle Aged; P | 2000 |
Biosynthesis and photodynamic efficacy of protoporphyrin IX (PpIX) generated by 5-aminolevulinic acid (ALA) or its hexylester (hALA) in rat bladder carcinoma cells.
Topics: Aminolevulinic Acid; Animals; Cell Extracts; Cell Survival; Culture Media; Culture Media, Serum-Free | 2000 |
Optimization of differential photodynamic effectiveness between normal and tumor urothelial cells using 5-aminolevulinic acid-induced protoporphyrin IX as sensitizer.
Topics: Aminolevulinic Acid; Flow Cytometry; Humans; Mitochondria; Photochemotherapy; Photosensitizing Agent | 2001 |
Autofluorescence imaging to optimize 5-ALA-induced fluorescence endoscopy of bladder carcinoma.
Topics: Administration, Intravesical; Aminolevulinic Acid; Biopsy; Cystoscopy; Equipment Design; False Posit | 2001 |
The fluorescence biodistribution and kinetics of aminolevulinic acid induced protoporphyrin IX in the bladder of a rat model with orthotopic urothelial carcinoma.
Topics: Administration, Intravesical; Aminolevulinic Acid; Animals; Carcinoma, Transitional Cell; Female; Fl | 2002 |